# ZSTK earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ZSTK) · [Earnings tab](https://www.lopjlb.com/stock/ZSTK?tab=earnings)

Updated: 2026-11-11T06:26:25

Quarters analyzed: 6

## Cross-quarter narrative

Flora Growth’s earnings narrative shows a rapid revenue expansion from a $9 million base in 2021 Q4 to a $37.2 million FY 2022 peak, driven by the JustCBD and Vessel brands and a Colombian export quota. The 2023‑24 period reflects a moderation, with Q2 2023 revenue of $21.5 million and Q1 2024 at $18 million, while German medical‑cannabis sales surged to $11.3 million. Gross margins peaked at 46.2% in Q3 2022 but fell sharply to roughly 18.6% by Q2 2023 as large impairments ($34.9 million) and discontinued‑operations losses were recorded. Cash balances contracted from $37.6 million in 2021 to $4.2 million in Q1 2024, prompting cost‑saving initiatives and a search for additional financing. The company pursued acquisitions (Franchise Global Health, TruHC) and divestitures (Colombian operations) while launching brand‑level partnerships, notably with Hulk Hogan. Market‑demand commentary remained positive for the House‑of‑Brands pillar, yet analysts flagged a broader market downturn and liquidity pressures. Regulatory optimism resurfaced in early 2024 with U.S. rescheduling expectations and expanded EU‑GMP capability.

## Latest CallCard · Q1

Flora Growth Q1 2024: $18M revenue, German medical cannabis sales jump to $11.3M, TruHC acquisition adds EU-GMP licenses, US rescheduling optimism, JustCBD/Vessel near breakeven, $4.2M cash.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks highlight transformational cannabis reform in Germ

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2024 Q1:** Flora Growth Q1 2024: $18M revenue, German medical cannabis sales jump to $11.3M, TruHC acquisition adds EU-GMP licenses, US rescheduling optimism, JustCBD/Vessel near breakeven, $4.2M cash.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks highlight transformational cannabis reform in Germ
- **2023 Q2:** Flora Growth Q2 2023: revenue $21.5M (+140% YoY), net loss $44.6M driven by $34.9M impairment and $7.6M discontinued ops; divested Colombian ops, cut $6.1M costs, focusing on Just Brands, Vessel, Phatebo; seeking additional financing. No analyst questions. 
- **2022 Q4:** Flora Growth reports FY2022 revenue of $37.2M (314% YoY), targets $100M in 2023 driven by House of Brands and Commercial Wholesale pillars, while integrating Franchise Global Health and advancing pharmaceutical trials. Cash fell to $9.5M after acquisitions. Impairment of $26.2M taken. Adjusted EBITD
- **2022 Q3:** Flora Growth reports record Q3 revenue of $10.8M (414% YoY), gross margin expands to 46.2%, advances Colombia cultivation exports, acquires Franchise Global Health for German medical cannabis distribution, targets $35-45M FY22 revenue.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Management emphasizes 
- **2022 Q2:** Flora Growth reports H1 2022 revenue up 604% YoY to $14.9M, reiterates full-year growth guidance of 300-400%, highlights Colombia cultivation progress with 43-ton THC quota, JustCBD integration, and life sciences clinical trials. Cash fell to $10.3M after acquisitions and inventory build; company re
- **2021 Q4:** Flora Growth reports 2021 revenue of $9M, guides 2022 revenue $35-45M (288-400% YoY), driven by House of Brands (JustCBD, Vessel) and Colombian cultivation expansion with new export quota. Gross margin expected to improve significantly as higher-margin brands scale. Cash balance $37.6M supports acqu

## Theme arcs

- **Revenue growth** (improving): Revenue rose from $9M in 2021 to $37M FY22 before moderating to $18‑21M in 2023‑24
- **Gross margin trajectory** (deteriorating): Margins peaked at 46% in Q3 2022 then fell to ~18.6% by Q2 2023
- **Cash position** (deteriorating): Cash fell from $37.6M (2021) to $4.2M (Q1 2024)
- **Guidance ambition** (new): 2022 guidance lifted to a $100M FY23 target, later omitted
- **Impairment impact** (deteriorating): Large $26.2M FY22 and $34.9M Q2 2023 impairments drove net losses
- **Cost‑reduction focus** (improving): $6.1M cost‑savings plan delivered in Q2 2023
- **Brand demand stability** (stable): Strong demand for JustCBD, Vessel and Phatebo cited throughout
- **Regulatory optimism** (new): U.S. rescheduling optimism and EU‑GMP licences highlighted in Q1 2024

## Fear persistence

- **Impairment and discontinued operations** [recurring]: Impairment losses cited in FY22 and Q2 2023
- **Market downturn** [new]: Downturn risk highlighted in Q2 2023
- **Liquidity risk** [new]: Need for additional financing noted in Q2 2023
- **Regulatory dependency** [new]: Regulatory outcomes described as upside in Q2 2023
- **Integration and execution risk** [new]: Execution risk mentioned in Q2 2023

## Guidance path

2021 Q4:vague → 2022 Q2:vague → 2022 Q3:vague → 2022 Q4:raised → 2023 Q2:vague → 2024 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ZSTK`